CD19 and neoplasm: Similar results were also observed using the same BCMA-targeting BsAb and LP-1 target tumor cells, a HER-2-targeting BsAb (with the Her2 antigen binding fragment, Fab, from Trastuzumab) and HER-2-expressing HCC1954 tumor cells, or a CD19-targeting BsAb and CD19-expressing Ocily19 cells, suggesting that our results are not restricted to this specific cell line model or target antigen (Supplementary Figure s 2B-G).